PT - JOURNAL ARTICLE AU - Poitrasson-Rivière, Alexis AU - Vanderver, Michael D. AU - Hagio, Tomoe AU - Arida-Moody, Liliana AU - Moody, Jonathan B. AU - Renaud, Jennifer M. AU - Ficaro, Edward P. AU - Murthy, Venkatesh L. TI - Automated Deep Learning Segmentation of Cardiac Inflammatory FDG PET AID - 10.1101/2024.01.31.24302113 DP - 2024 Jan 01 TA - medRxiv PG - 2024.01.31.24302113 4099 - http://medrxiv.org/content/early/2024/02/03/2024.01.31.24302113.short 4100 - http://medrxiv.org/content/early/2024/02/03/2024.01.31.24302113.full AB - Background Fluorodeoxyglucose positron emission tomography (FDG PET) with glycolytic metabolism suppression plays a pivotal role in diagnosing cardiac sarcoidosis. Reorientation of images to match perfusion datasets is critical and myocardial segmentation enables consistent image scaling and quantification. However, both are challenging and labor intensive. We developed a 3D U-Net deep learning (DL) algorithm for automated myocardial segmentation in cardiac sarcoidosis FDG PET.Methods The DL model was trained on 316 patients’ FDG PET scans, and left ventricular contours derived from perfusion datasets. Qualitative analysis of clinical readability was performed to compare DL segmentation with the current automated method on a 50-patient test subset. Additionally, left ventricle displacement and angulation, as well as SUVmax sampling were compared to inter-user reproducibility results.Results DL segmentation enhanced readability scores in over 90% of cases compared to the standard segmentation currently used in the software. DL segmentation performed similarly to a trained technologist, surpassing standard segmentation for left ventricle displacement and angulation, as well as correlation of SUVmax.Conclusion The DL-based automated segmentation tool presents a marked improvement in the processing of cardiac sarcoidosis FDG PET, promising enhanced clinical workflow. This tool holds significant potential for accelerating clinical practice and improving consistency and quality. Further research with varied datasets is warranted to broaden its applicability.Competing Interest StatementAPR, JBM, JMR, and MV are employees of INVIA. JMR is a consultant for Jubilant Radiopharma and receives royalties from licensing of the FlowQuant software. EPF is a stockholder in INVIA. VLM has received research grants and speaking honoraria from Siemens Medical Imaging and serves as a scientific advisor for Ionetix and owns stock options in the same. He owns stock in GE and Cardinal Health, has received expert witness payments on behalf of Jubilant Radiopharma and a speaking honorarium from 2Quart Medical, and receives consulting payments and research support from INVIA. He is also supported by grants R01AG059729 from the National Institute on Aging, U01DK123013 from the National Institute of Diabetes and Digestive and Kidney Disease, and R01HL136685 from the National Heart, Lung, and Blood Institute.Funding StatementThis study was funded solely by INVIA Medical Imaging Solutions.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All data were anonymized, and informed consent was waived under an exemption from the University of Michigan Institutional Review Board (HUM00023712).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data used in this study are the property of the University of Michigan and cannot be shared without a data use agreement with them.